Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer

This article was originally published here

The results, which were presented as a short oral presentation, included preliminary safety and efficacy data from an ongoing multicenter, open-label, dose-escalation study, which aims to determine the

The post Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply